Friday, July 10, 2026

Drug profile · INN

pasireotide

pasireotide (SIGNIFOR) is a somatostatin receptor 1 agonist.

EMA: approved Systemic hormonal preparations (H01) H01CB05
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — pasireotide
Class
Systemic hormonal preparations (H01)
Route
Patents
0
Programs
4
Data quality
0.83

Quick answer

pasireotide (SIGNIFOR) is a somatostatin receptor 1 agonist.

Key facts

INN pasireotide
Brand SIGNIFOR
Mechanism Somatostatin receptor 1 agonist
Therapeutic class Systemic hormonal preparations (H01)
ATC code H01CB05

Mechanism of action

Somatostatin receptor 1 agonist

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. SOM230-RECAG-CL-0576 Phase 2 · Recordati Ireland · Post-Bariatric Hypoglycaemia
  2. SOM 230 / Pasireotide Phase 1 · United Therapeutics Europe · Atypical Ductal Breast Hyperplasia
  3. SOM230-RECAG-PK-0605 Phase 1 · Recordati Ireland · Post-bariatric hypoglycaemia
  4. SOM230-RECAG-PK-612 Phase 1 · Recordati Ireland · Post-bariatric hypoglycaemia

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is pasireotide?

pasireotide (SIGNIFOR) is a somatostatin receptor 1 agonist.

What is the brand name for pasireotide?

SIGNIFOR is a marketed brand name for pasireotide. Check FDA Drugs@FDA for the current US label holder and prescribing information.